Combining HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia
26 giugno 2026 aggiornato da: Hsin-An Chang, MD, Tri-Service General Hospital (TSGH)
The Efficacy of Combined HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia
Dysfunction of the dorsolateral prefrontal cortex (DLPFC) is central to the persistence of negative symptoms in schizophrenia.
Both HD-tDCS and iTBS targeting the left DLPFC have shown therapeutic benefit.
This trial will test the hypothesis that combining HD-tDCS with iTBS yields additive efficacy.
Panoramica dello studio
Stato
Iscrizione su invito
Descrizione dettagliata
Dysfunction of the left dorsolateral prefrontal cortex (DLPFC) is central to the persistence of negative symptoms in schizophrenia, an area of unmet therapeutic need.
High-definition transcranial direct current stimulation (HD-tDCS) and intermittent theta burst stimulation (iTBS), an optimized form of repetitive transcranial magnetic stimulation (rTMS), have each demonstrated efficacy in alleviating negative symptoms when applied to the left DLPFC.
However, meta-analyses indicate only moderate effect sizes for these interventions individually.
Evidence suggests that combining iTBS with tDCS may enhance cortical plasticity beyond either technique alone, warranting trials to assess additive efficacy.
This double-blind, randomized, sham-controlled study will test the hypothesis that combined HD-tDCS and iTBS produce superior therapeutic benefit for negative symptoms in schizophrenia.
Tipo di studio
Interventistico
Iscrizione (Stimato)
100
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
-
Taipei, Taiwan, 114
- Tri-Service General Hospital
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
No
Descrizione
Inclusion Criteria:
- Subjects diagnosed with DSM-5 schizophrenia or schizoaffective disorder;
- With a clinical presentation characterized by predominant negative symptoms, as determined by psychiatric assessment and a score of at least 20 on the Negative Symptoms Subscale of the Positive and Negative Syndrome Scale (PANSS);
- Stable positive and negative symptoms for at least 4 weeks, as documented in medical records and confirmed by clinical judgment and psychiatric interview;
Exclusion Criteria:
- Unstable medical conditions;
- Current psychiatric comorbidity or active substance use disorder (except for tobacco use disorders);
- Contraindications for MRI, tDCS or rTMS;
- Pregnancy or breastfeeding at the time of enrollment;
- History of meningitis, encephalitis, seizures, intracranial neoplasms or surgery, severe head injury or cerebrovascular disease, or a family history of seizures;
- rTMS or tDCS treatment within the past 6 months as well as a history of electroconvulsive therapy (ECT);
- Any skin lesion at the stimulation sites;
- Patients receiving medications that significantly change the seizure threshold;
- A history of suicidal behavior within the past 6 months, or symptom worsening and emergence of suicidal ideation during the screening period.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: active iTBS followed by active HD-tDCS
During the 3-week intervention phase, patients in this group will receive 2 sessions of active iTBS per working day for 2 weeks (totaling 20 sessions), followed by 2 sessions of active HD-tDCS per working day for 1 week (totaling 10 sessions).
|
The active iTBS sessions will be delivered using the Magstim Rapid2 stimulator.
The iTBS protocol consists of 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) for 2 s at 8-s intervals for 60 cycles.
A 2-s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session.
The intensity of stimulation will be set at 80% resting motor threshold (RMT).
The target will be the left DLPFC with the coil centered at the MNI coordinate [-38, 44, 26] calculated from T1-weighted MRI.
The active HD-tDCS will be applied by NeuroConn DC Stimulator Plus.
The central anode will be placed over the International 10-20 electrode position F3 and the return peripheral electrodes placed at Fp1, Fz, C3 and F7.
Stimulation session will be applied at an intensity of 2 mA, 8-sec fade in and 5-sec fade out, for 20 min.
During each session, the subject has to perform a computerized working memory task (i.e., 2-back task).
The two times daily sessions will be separated by at least 2 hours.
|
|
Sperimentale: sham iTBS followed by active HD-tDCS
During the 3-week intervention phase, patients in this group will receive 2 sessions of sham iTBS per working day for 2 weeks (totaling 20 sessions), followed by 2 sessions of active HD-tDCS per working day for 1 week (totaling 10 sessions).
|
In the sham iTBS condition, the patients receive the same iTBS regimen and exact positioning of the coil but stimulations will be delivered using a commercial identical looking figure 8 sham coil (Magstim D70 Air film sham coil) that can produce a similar sound and sensation.
In the active HD-tDCS condition, stimulation will be applied by a battery-operated device (NeuroConn DC Stimulator Plus) via 5 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration).
To target the left DLPFC, the central electrode (anode) will be placed over International 10-20 electrode position F3, with return peripheral electrodes at Fp1, Fz, C3 and F7.
Stimulation will be applied at an intensity of 2 milliamp (mA), 8-sec fade in and 5-sec fade out, for 20 min.
During each session, the subject has to perform a computerized working memory task (i.e., 2-back task).
The two times daily sessions will be separated by at least 2 hours.
|
|
Sperimentale: active iTBS followed by sham HD-tDCS
During the 3-week intervention phase, patients in this group will receive 2 sessions of active iTBS per working day for 2 weeks (totaling 20 sessions), followed by 2 sessions of sham HD-tDCS per working day for 1 week (totaling 10 sessions).
|
The active iTBS sessions will be delivered using the Magstim Rapid2 stimulator.
The iTBS protocol consists of 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) for 2 s at 8-s intervals for 60 cycles.
A 2-s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session.
The intensity of stimulation will be set at 80% resting motor threshold (RMT).
The target is the left DLPFC with the coil centered at the MNI coordinate [-38, 44, 26] calculated from T1-weighted MRI.
In the sham HD-tDCS stimulation, short continuous currents without neuromodulatory effects will be applied to mimic real-stimulation sensations.
Specifically, sham stimulation will deliver 40-sec, 2 mA normal-like stimulation, followed by a tiny current pulse (110 μA over 15 ms) for impedance control taking place every 550 ms for the remaining time.
The other procedure is the same as the active HD-tDCS stimulation.
|
|
Comparatore fittizio: sham iTBS followed by sham HD-tDCS
During the 3-week intervention phase, patients in this group will receive 2 sessions of sham iTBS per working day for 2 weeks (totaling 20 sessions), followed by 2 sessions of sham HD-tDCS per working day for 1 week (totaling 10 sessions).
|
In the sham iTBS condition, patients receive the same iTBS regimen and exact positioning of the coil but stimulations will be delivered using a commercial identical looking figure 8 sham coil (Magstim D70 Air film sham coil) that can produce a similar sound and sensation.
In the sham HD-tDCS condition, short continuous currents without neuromodulatory effects will be applied to mimic real-stimulation sensations.
Specifically, sham stimulation will deliver 40-sec, 2 mA normal-like stimulation, followed by a tiny current pulse (110 μA over 15 ms) for impedance control taking place every 550 ms for the remaining time.
The other procedure is the same as the active HD-tDCS stimulation.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The change in Positive and Negative Syndrome Scale (PANSS) negative subscale score
Lasso di tempo: Fifteen weeks
|
PANSS is a clinician-administered rating scale to measure the severity of psychopathological symptoms of the patients with schizophrenia spectrum disorder. The patient is rated from 1 to 7 on 30 different symptom items. All items scores are summed up to yield a total PANSS score, which ranges from 30 to 210. A higher score indicates greater psychopathological symptom severity. PANSS negative subscale has 7 items with its score ranging from 7 to 49. The changes in the PANSS negative subscale score immediately after the 3-week intervention (primary endpoint), as well as at one-month and three-month follow-ups, will be collected as the primary outcome. |
Fifteen weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The change in score of the Scale for the Assessment of Negative Symptoms (SANS)
Lasso di tempo: Fifteen weeks
|
The Scale for the Assessment of Negative Symptoms (SANS) is used to assess negative symptoms in schizophrenia on a 25 item, 6-point scale.
The SANS measures five domains of the negative symptoms including affective flattening or blunting, alogia, avolition - apathy, anhedonia - Asociality, Attention.
In each domain, separate symptoms are rated from 0 (absent) to 5 (severe).
A total SANS score ranges from 0 to 125.
The changes in the SANS score immediately after the 3-week intervention, as well as at one-month and three-month follow-ups, will be collected as the secondary outcome.
|
Fifteen weeks
|
|
The change in score of Calgary Depression Rating Scale for Schizophrenia (CDSS)
Lasso di tempo: Fifteen weeks
|
The participants' depressive symptoms will be measured by Calgary Depression Rating Scale for Schizophrenia (CDSS).
The changes in the CDSS score immediately after the 3-week intervention, as well as at one-month and three-month follow-ups, will be collected as the secondary outcome.
|
Fifteen weeks
|
|
The change in the Personal and Social Performance scale (PSP) score
Lasso di tempo: Fifteen weeks
|
PSP is a clinician-administered rating scale for measuring the psychosocial functioning of the patients with schizophrenia spectrum disorder. The PSP scale measures psychosocial functioning within four domains: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior.The patient is rated from 1 to 6 on each item of the four domains. A higher score indicates greater psychosocial functioning in any of the four domains. The final global score is defined according to a summary instruction table. This scale provides a single, overall rating from 1 to 100, where a higher score represents better personal and social function. The changes in the Personal and Social Performance scale (PSP) score immediately after the 3-week intervention, as well as at one-month and three-month follow-ups, will be collected as the secondary outcome. |
Fifteen weeks
|
|
The change in the score of the Beck Cognitive Insight Scale (BCIS)
Lasso di tempo: Fifteen weeks
|
Cognitive insight was measured by the Taiwanese version of the Beck Cognitive Insight Scale (BCIS), a self-reported instrument comprising 15 items.The Taiwanese BCIS is composed of 2 subscales including reflective attitude (9 items) and certain attitude (6 items).
We obtained a R-C (reflective attitude minus certain attitude) index of the Taiwanese BCIS, representing the measurement of cognitive insight by subtracting the score of the certain attitude subscale from that of the reflective attitude subscale.
Lower R-C index scores indicate poorer cognitive insight.
The changes in the score of the Beck Cognitive Insight Scale (BCIS) immediately after the 3-week intervention, as well as at one-month and three-month follow-ups, will be collected as the secondary outcome.
|
Fifteen weeks
|
|
The change in the score of Schizophrenia Quality of Life Scale Revision Four (SQOLR4)
Lasso di tempo: Fifteen weeks
|
The Chinese version of the Schizophrenia Quality of Life Scale Revision Four (SQOLR4) is a self-administered questionnaire of 33 items in two domains: psychosocial and vitality. All but four items are coded on a scale of 0-4 according to the frequency of occurrence during the previous 7 days (0 = always, 4 = never; the four exceptions are coded 0 = never, 4 = always). A higher score indicates higher health-related QoL. The changes in the score of Schizophrenia Quality of Life Scale Revision Four (SQOLR4) immediately after the 3-week intervention, as well as at one-month and three-month follow-ups, will be collected as the secondary outcome. |
Fifteen weeks
|
|
The changes in the results of the Tower of London Drexel University Test 2nd Edition
Lasso di tempo: Three weeks
|
The Tower of London Drexel University Test 2nd Edition is a neuropsychological test for the assessment of executive functioning specifically to detect deficits in planning, which may occur due to a variety of medical and neuropsychiatric conditions.
The changes in the results of the Tower of London Drexel University Test 2nd Edition immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
|
The changes in the results of the Color Trails Test (CTT)
Lasso di tempo: Three weeks
|
The CTT, a culture-neutral version of the Trail Making Test, was selected to measure sustained visual attention.
The CTT consists of two parts (CTT-1 and CTT-2).
The CTT-1 requires participants to connect a series of numbered circles that are randomly printed on a sheet of paper.
In the CTT-2, numbered circles of 1 to 25 are shown twice (printed in pink and in yellow) randomly on a sheet of paper.
Participants are asked to connect the numbers from 1 to 25 alternating between the two colors.
The changes in the results of the Color Trails Test (CTT) immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
|
The changes in the results of the Stroop Color Word Test (SCWT)
Lasso di tempo: Three weeks
|
Stroop Color Word Test (SCWT) will be administered to measure selective attention and cognitive flexibility.
SCWT is composed of three parts, each lasting for 45 seconds.
The changes in the results of the Stroop Color Word Test (SCWT) immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
|
The changes in indices of heart rate variability (HRV)
Lasso di tempo: Three weeks
|
HRV indices represent autonomic functioning. ECG electrodes will be placed on bilateral arms just below the elbows, with a ground electrode placed just above the right wrist bone. Lead I electrocardiogram of each patient will be taken for 5 min after sitting and having a rest for 20 min in a soundproof, dim-lighted room with thermostatic control. The ECG signals will be acquired, stored, pre-processed according to the recommended procedures and processed by an HRV analyser. The time domain of HRV is obtained: Standard deviation of NN intervals (SDNN). Power spectrum of HRV is quantified into the standard frequency-domain measurements including low-frequency power (LF, 0.04-0.15 Hz), high-frequency power (HF, 0.15- 0.40 Hz). The changes in indices of heart rate variability (HRV) immediately after the 3-week intervention will be collected as the secondary outcome. |
Three weeks
|
|
The changes in resting-state EEG features
Lasso di tempo: Three weeks
|
In a dimly lit, electrically shielded room, patients' electroencephalogram (EEG) will be recorded.
Resting-state EEG will be collected with eye opened (5min) and closed (5min).
Signals will be amplified by using EEG amplifiers and stored for offline analyses.
The changes in resting-state EEG features immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
|
The changes in fNIRS features
Lasso di tempo: Three weeks
|
Functional near infrared spectroscopy (fNIRS) system is used to measure the relative changes in oxyhemoglobin (Hb) of the frontal regions.
Resting-state fNIRS fo 180s and verbal fluency task (VFT)-based fNIRS for 160s will be collected in a quiet room.
The changes in fNIRS features immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
|
The changes in resting-state fMRI features
Lasso di tempo: Three weeks
|
Magnetic Resonance Imaging (MRI) scans will be performed on the hybrid 3.0T PET-MR imaging unit (GE Healthcare, Waukesha, WI).
MRI scans will be carried out using the same imaging protocol, including T1-weighted images and resting-state functional MRI (rs-fMRIs).The changes in resting-state fMRI features immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Collaboratori
Investigatori
- Investigatore principale: Hsin-An Chang, M.D., Tri-Service General Hospital (TSGH)
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Pubblicazioni generali
- Kishi T, Ikuta T, Sakuma K, Hamanaka S, Nishii Y, Hatano M, Kito S, Iwata N. Theta Burst Stimulation Protocols for Schizophrenia: A Systematic Review and Network Meta-Analysis. JAMA Netw Open. 2024 Oct 1;7(10):e2441159. doi: 10.1001/jamanetworkopen.2024.41159.
- Tong S, Chen S, Chen J, Tong Z, Li W, Liu S, Shi H, Yao L, Zhang C, Zhang X. Efficacy and long-term effects of intermittent theta burst stimulation on negative symptoms in schizophrenia: a systematic review and meta-analysis. Brain Commun. 2026 Jan 29;8(1):fcag027. doi: 10.1093/braincomms/fcag027. eCollection 2026.
- Gupta R, Sharma A, Goyal N. Breaking the Negative Symptom Barrier: A Novel Neuromodulation Strategy Using HD-tDCS Primed iTBS in Schizophrenia. J ECT. 2026 Jan 20. doi: 10.1097/YCT.0000000000001224. Online ahead of print.
- Ma CC, Lin YY, Chung YA, Park SY, Huang CC, Chang WC, Chang HA. The two-back task leads to activity in the left dorsolateral prefrontal cortex in schizophrenia patients with predominant negative symptoms: a fNIRS study and its implication for tDCS. Exp Brain Res. 2024 Mar;242(3):585-597. doi: 10.1007/s00221-023-06769-5. Epub 2024 Jan 16.
- Yeh TC, Lin YY, Tzeng NS, Kao YC, Chung YA, Chang CC, Fang HW, Chang HA. Effects of online high-definition transcranial direct current stimulation over left dorsolateral prefrontal cortex on predominant negative symptoms and EEG functional connectivity in patients with schizophrenia: a randomized, double-blind, controlled trial. Psychiatry Clin Neurosci. 2025 Jan;79(1):2-11. doi: 10.1111/pcn.13745. Epub 2024 Sep 24.
- Lin CE, Chen LF, Sack AT, Chang HA. Task-based fNIRS biomarkers of HD-tDCS treatment for negative symptoms in schizophrenia. Schizophr Res. 2026 Aug;294:35-43. doi: 10.1016/j.schres.2026.04.010. Epub 2026 Apr 17.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
6 maggio 2024
Completamento primario (Stimato)
31 dicembre 2027
Completamento dello studio (Stimato)
1 marzo 2028
Date di iscrizione allo studio
Primo inviato
26 giugno 2026
Primo inviato che soddisfa i criteri di controllo qualità
26 giugno 2026
Primo Inserito (Effettivo)
2 luglio 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
2 luglio 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
26 giugno 2026
Ultimo verificato
1 giugno 2026
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- B202303001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
NO
Descrizione del piano IPD
Individual participant data (IPD) will not be shared, as required by the local ethics committee to protect patient privacy.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
prodotto fabbricato ed esportato dagli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .